Clinical Trials Logo

Filter by:
NCT ID: NCT04796623 Recruiting - Clinical trials for HR-positive, HER2-negative Advanced Breast Cancer

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Start date: February 4, 2021
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 and Cohort 2. Each cohort will enroll 30-60 cases.

NCT ID: NCT04796467 Recruiting - Prostate Cancer Clinical Trials

68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Start date: October 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the widely studied 68Ga-PSMA-617. This pilot study was prospectively designed to evaluate the early dynamic distribution of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-617 in the same group of prostate cancer patients.

NCT ID: NCT04796441 Recruiting - AML Clinical Trials

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

Start date: December 16, 2020
Phase: N/A
Study type: Interventional

This is an open single-arm clinical study aimed at evaluating the efficacy and safety of universal γδT cell injection in the treatment of patients with relapsed AML after transplantation

NCT ID: NCT04796025 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study

T-Double
Start date: September 23, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with pd-1 antibody immunotherapy (Sintilimab) and anti-VEGF (Bevacizumab Biosimilar) in patients with advanced hepatocellular carcinoma (BCLC-C Stage).

NCT ID: NCT04795973 Recruiting - Clinical trials for Individuals With Metabolic Disease

Efficacy of Intermittent Fasting on Metabolic Disease

Start date: September 22, 2020
Phase: N/A
Study type: Interventional

To elucidate the health effects, and further explore the research on safety. This study was conducted among adults with metabolic disease by using the intermittent fasting for 4 weeks. The aim of this study is to provide scientific basis for the IF used as a new prevention and control technology for metabolic disease.

NCT ID: NCT04795453 Recruiting - Surgery Clinical Trials

Assessment of Score System of Surgery in Necrotizing Enterocolitis(NEC) Patients

Start date: March 1, 2021
Phase:
Study type: Observational

Necrotizing enterocolitis(NEC) is one of the most serious disease in the newborn infants, and two and more grades of NEC usually lead to surgery, even death. But, it is difficult to predict when to operate the surgery.

NCT ID: NCT04795414 Recruiting - Covid19 Clinical Trials

Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers

Start date: January 14, 2021
Phase:
Study type: Observational

With the unprecedented morbidity of the COVID-19 pandemic, the vaccine effectiveness needs to be assessed across diverse populations. The purpose of this study is to evaluate the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in medical workers.

NCT ID: NCT04795128 Recruiting - Clinical trials for Hematologic Malignancy

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Start date: May 7, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with hematologic malignancies who have failed standard treatment.

NCT ID: NCT04794972 Recruiting - Solid Tumor Clinical Trials

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Start date: April 14, 2021
Phase: Phase 1
Study type: Interventional

In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.

NCT ID: NCT04794738 Recruiting - Pain Clinical Trials

A Clinical Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery

Start date: April 18, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective is to evaluate the analgesic efficacy of IV SHR8554 compared with placebo and morphine in patients with acute postoperative pain following orthopedic surgery.